The DOI matches its Crossref record; 211 of the 211 references it cites were found in a registry or an index.
Antisense technology: A review
Open accessAbstract
Antisense technology is beginning to deliver on the broad promise of the technology. Ten RNA-targeted drugs including eight single-strand antisense drugs (ASOs) and two double-strand ASOs (siRNAs) have now been approved for commercial use, and the ASOs in phase 2/3 trials are innovative, delivered by multiple routes of administration and focused on both rare and common diseases. In fact, two ASOs are used in cardiovascular outcome studies and several others in very large trials. Interest in the technology continues to grow, and the field has been subject to a significant number of reviews. In this review, we focus on the molecular events that result in the effects observed and use recent clinical results involving several different ASOs to exemplify specific molecular mechanisms and specific issues. We conclude with the prospective on the technology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–211 of 211
Gale, J. D., Jensen, J., Berman, G., Freimuth, W. W., Li, G., Pleil, A. M., Kutty, M., Rosenthal, A., Boswell, C., V., E. M. N., et al. (2018) · Plastic & Reconstructive Surgery Global Open · doi:10.1097/gox.0000000000001861 · Cited by 14
Phosphorothioate Antisense Oligonucleotides Bind P-Body Proteins and Mediate P-Body Assembly
Wang, Y., Shen, W., Liang, X., & Crooke, S. T. (2019) · Nucleic Acid Therapeutics · doi:10.1089/nat.2019.0806 · Cited by 14
Self-citationInteraction of ASOs with PC4 Is Highly Influenced by the Cellular Environment and ASO Chemistry
Vickers, T. A., Migawa, M. T., Seth, P. P., & Crooke, S. T. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c01808 · Cited by 14
Self-citation10th Annual Meeting of the Oligonucleotide Therapeutics Society
Gagnon, K. T., Watts, J. K., & on behalf of the Board of the Oligonucleotide Therapeutics Society (2014) · Nucleic Acid Therapeutics · doi:10.1089/nat.2014.1502 · Cited by 13
Alicaforsen in the Treatment of Pouchitis
Greuter, T., & Rogler, G. (2017) · Immunotherapy · doi:10.2217/imt-2017-0085 · Cited by 13
Routes and Formulations for Delivery of Antisense Oligonucleotides
Hardee, G. E., Tillman, L., & Geary, R. S. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-15 · Cited by 12
Pollak, A. J., Hickman, J. H., Liang, X., & Crooke, S. T. (2020) · Nucleic Acid Therapeutics · doi:10.1089/nat.2020.0864 · Cited by 10
Self-citationMcGowan, M. P., Moriarty, P. M., & Backes, J. M. (2014) · Clinical Lipidology · doi:10.2217/clp.14.43 · Cited by 8
Mignon, L., Norris, D. A., Bishop, K. M., Derosier, F. J., Lane, R. M., & Bennett, F. (2016) · Neurology · doi:10.1212/wnl.86.16_supplement.p3.166 · Cited by 8
Sigova, A. A., & Zamore, P. D. (2007) · CRC Press eBooks · doi:10.1201/9780849387951-9 · Cited by 6
Wagner, K. R., Phan, H. C., Servais, L., Gidaro, T., Cripe, L. H., Eagle, M., Muntoni, F., Straub, V. W., Lonkar, P., Schmitz, S., et al. (2019) · Neuromuscular Disorders · doi:10.1016/j.nmd.2019.06.311 · Cited by 5
Cited by
Knockdown of Amyloid Precursor Protein: Biological Consequences and Clinical Opportunities
Gabriele, R. M. C., Abel, E., Fox, N. C., Wray, S., & Arber, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.835645 · Cited by 44
Mapping PTBP2 binding in human brain identifies SYNGAP1 as a target for therapeutic splice switching
Dawicki-McKenna, J. M., Felix, A. J., Waxman, E. A., Cheng, C., Amado, D. A., Ranum, P. T., Bogush, A., Dungan, L. V., Maguire, J. A., Gagne, A. L., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38273-3 · Cited by 41
Wu, A.-X., Wang, X.-J., Zhao, C., Hu, J.-Q., Li, J.-W., Xu, Y., Li, Y., & Liu, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108178 · Cited by 1
Metadata
- Authors
- Crooke, S. T., Liang, X.-H., Baker, B. F., & Crooke, R. M.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 296
- Pages
- 100416
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W3131848822
- Cited by
- 326
- References
- 211
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.